RESULTS Seventy nine patients were identified (seven dead, 72 transplanted). Two patients (2.5%) were heterozygous for the Z allele of α 1-AT and four (5.1%) were heterozygous for the S allele. This ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Korro Bio (KRRO) announced the initiation of dosing in its REWRITE study investigating KRRO-110 as a potential treatment for individuals with ...

Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease ...

Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report) and keeping the ...

Michael Shaw, aged 24, of Bride Street, Todmorden is due to appear at Bradford magistrates' court today (Tuesday) charged ...

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company at the forefront of precision genetic medicines with a market capitalization of $1.87 billion, is navigating a critical juncture in its ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

Although no cause of death or further details were given, the news comes months after Lynch announced he had been living with ...

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.